Page 59 - GPD-3-2

Gene & Protein in Disease TOPK: Target for lung cancer treatment

A B

C D

E

Figure 1. PBK expression in LUAD and LUSC. (A and B) TOPK expression in LUAD based on sample types (A) and gender of patients (B); data
obtained from The Cancer Genome Atlas database. (C and D) TOPK expression in LUSC based on sample types (C) and gender of patients (D). (E)
Gene expression profiles in all tumor samples paired with normal tissue. The height of the bars indicates the median expression of a certain tumor type
or normal tissue. ***P < 0.001. Source: Diagram made by the authors.
Abbreviations: TOPK: T-LAK cell-originated protein kinase; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma.

NSCLC cells with MET amplification-induced gefitinib predicted poor prognosis. 20,23,24 Similarly, after analyzing
resistance. Thus, TOPK may serve as a novel target for 127 patients with LUAD, it was found that high expression
22
overcoming resistance to gefitinib. of TOPK and mutant P53, as well as lymph node metastasis
and distant metastasis, were found to be independent
2.3. TOPK as a prognostic indicator of lung cancer predictors of poor prognosis in patients with LUAD.
25
Accumulating evidence indicates that TOPK is a Recently, one study based on the Oncomine database
marker of poor prognosis in lung cancer patients. Early showed that TOPK levels were negatively correlated with
immunohistochemical analysis revealed that patients with the OS of lung cancer patients, particularly those with
high expression of TOPK in stage I NSCLC were more likely LUAD. Subgroup analysis suggested that overexpression
to experience recurrence and metastasis, and their overall of TOPK was related with a significantly shorter survival
survival (OS) rate was lower than that of patients with low period in patients classified by sex, grade, and clinical
expression of TOPK; moreover, high expression of TOPK stage, with the exception of Stage 4 lung cancer patients

Volume 3 Issue 2 (2024) 3 doi: 10.36922/gpd.3062